You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Recurrent Ovarian Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Participation Patterns Among Recurrent Ovarian Cancer Patients

Not yet recruiting
  • Recurrent Ovarian Cancer
    • San Francisco, California
      Power Life Sciences
    Sep 30, 2023

    Ovarian Cancer Recurrent Trial (Fluzopril Combined With Apatinib)

    Not yet recruiting
    • Ovarian Cancer Recurrent
    • Fluzopril Combined With Apatinib
    • (no location specified)
    Oct 22, 2023

    Recurrent Ovarian Cancer Trial in Pittsburgh (CPI-0209, carboplatin)

    Not yet recruiting
    • Recurrent Ovarian Cancer
    • Pittsburgh, Pennsylvania
      Magee-Womens Research Institute / UPMC Magee Womens Hospital
    Jul 3, 2023

    Recurrent Ovarian Cancer Trial (DOXIL, Withaferin A, Ashwagandha)

    Not yet recruiting
    • Recurrent Ovarian Cancer
    • (no location specified)
    Jan 27, 2023

    Ovarian Cancer Recurrent Trial in Beijing (IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin)

    Recruiting
    • Ovarian Cancer Recurrent
    • Beijing, China
      Cancer Hospital Chinese Academy of Medical Science and Peking Un
    Aug 23, 2023

    Platinum-resistant Ovarian Cancer Trial in Shanghai (Oral Topotecan Combined With Anlotinib)

    Not yet recruiting
    • Platinum-resistant Ovarian Cancer
    • Oral Topotecan Combined With Anlotinib
    • Shanghai, China
      Xinhua Hospital Affiliated to Shanghai Jiaotong University Schoo
    Feb 12, 2023

    Ovarian Cancer Recurrent Trial in Birmingham (M4344+Niraparib)

    Not yet recruiting
    • Ovarian Cancer Recurrent
    • Birmingham, Alabama
      University of Alabama at Birmingham
    Jan 5, 2023

    Recurrent Ovarian Cancer Trial in Shanghai (Fuzuloparib Combination with Bevacizumab)

    Not yet recruiting
    • Recurrent Ovarian Cancer
    • Fuzuloparib Combination with Bevacizumab
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Cente
    Apr 14, 2023

    Ovarian Cancer Trial (Gleolan)

    Not yet recruiting
    • Ovarian Cancer
    • (no location specified)
    Mar 27, 2023

    Cytoreductive Surgery Trial in Hangzhou (cytoreductive surgery)

    Not yet recruiting
    • Cytoreductive Surgery
    • cytoreductive surgery
    • Hangzhou, China
    • +1 more
    Nov 30, 2022

    Ovarian Tumors, Recurrent Ovarian Carcinoma, Relapsed Ovarian Cancer Trial in Beijing (AK112 low dose, AK112 medium dose, AK112

    Terminated
    • Ovarian Neoplasms
    • +3 more
    • AK112 low dose
    • +2 more
    • Beijing, Beijing, China
      Chinese Academy of Medical Sciences and Peking Union Medical Col
    Oct 8, 2022

    Recurrent Ovarian Cancer, Recurrent Uterine Cancer, Metastatic Cancer Trial in Toronto (RP-6306, Carboplatin, Paclitaxel)

    Not yet recruiting
    • Recurrent Ovarian Cancer
    • +3 more
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Oct 25, 2023

    Recurrent Ovarian Cancer Trial in Bochum (chemo with doxorubicin and cisplatin)

    Completed
    • Recurrent Ovarian Cancer
    • chemotherapy with doxorubicin and cisplatin
    • Bochum, NRW, Germany
      Ruhr University Bochum
    Jul 7, 2022

    Ovarian Cancer Trial in Hangzhou (NKG2D CAR-NK)

    Recruiting
    • Ovarian Cancer
    • NKG2D CAR-NK
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    Mar 26, 2023

    Platinum-resistant Recurrent Ovarian Cancer Trial in Wuhan (Docetaxel for injection (Albumin-bound), Bevacizumab)

    Recruiting
    • Platinum-resistant Recurrent Ovarian Cancer
    • Wuhan, Hubei, China
      Tongji Hospital,Tongji Medical College of HUST
    Oct 12, 2022

    Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer Trial in Durham, Oklahoma

    Recruiting
    • Recurrent Ovarian Cancer
    • +6 more
    • Durham, North Carolina
    • +2 more
    Jul 26, 2022

    Ovarian Cancer, Endometrial Cancer, Recurrent Ovarian Cancer Trial (BKM120, Nabpaclitaxel)

    Withdrawn
    • Ovarian Cancer
    • +3 more
    • (no location specified)
    Jul 27, 2022

    Ovarian Cancer Trial (Aribulin;carboplatin;bevacizumab)

    Not yet recruiting
    • Ovarian Cancer
    • (no location specified)
    Jul 20, 2023

    Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or

    Recruiting
    • Ovarian Cancer
      • Seoul, Korea, Republic of
        Yonsei University Health System, Severance Hospital
      Jul 13, 2022

      Epithelial Ovarian Cancer Trial in Goyang-si (HIPEC)

      Recruiting
      • Epithelial Ovarian Cancer
      • HIPEC
      • Goyang-si, Gyeonggi-do, Korea, Republic of
        Myong Cheol Lim
      Apr 23, 2022

      Recurrent Epithelial Ovarian Cancer Trial in Seoul (Standard salvage therapy, Standard salvage therapy + SABR)

      Recruiting
      • Recurrent Epithelial Ovarian Cancer
      • Standard salvage therapy
      • Standard salvage therapy + SABR
      • Seoul, Korea, Republic of
        Yonsei University Health System, Severance Hospital
      Jun 29, 2022

      Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Pittsburgh (ZEN003694, Talazoparib)

      Recruiting
      • Ovarian Cancer
      • +2 more
      • Pittsburgh, Pennsylvania
        University of Pittsburgh Medical Center
      Apr 27, 2022

      Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

      Not yet recruiting
      • Ovarian Clear Cell Adenocarcinoma
      • +14 more
      • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
      • +4 more
      • Buffalo, New York
      • +1 more
      Dec 16, 2022

      Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV Trial in Seoul (Oregovomab, Bevacizumab,

      Recruiting
      • Ovarian Cancer by FIGO Stage
      • +2 more
      • Oregovomab
      • +3 more
      • Daegu, Korea, Republic of
      • +5 more
      Oct 20, 2022

      Ovarian Tumors Trial in Chongqing

      Recruiting
      • Ovarian Neoplasms
        • Chongqing, Chongqing, China
          Chongqing University Cancer Hospital
        Mar 12, 2022